Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Summary

This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

Timeline

Start

2007-01

Primary completion

2010-10

Completion

2010-10

Drugs

Indications